Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia

Cognitive deficits represent a core feature of schizophrenia. Previous studies have demonstrated that plasma asymmetric dimethylarginine (ADMA) was increased in patients with schizophrenia and correlated with cognitive impairments. Atypical antipsychotics can produce cognitive benefits in schizophre...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Zhi-min, Zhao, Ying, Zhan, Jin-qiong, Luo, Tao, Xiong, Jian-wen, Yu, Bin, Wei, Bo, Yang, Yuan-jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335386/
https://www.ncbi.nlm.nih.gov/pubmed/30687138
http://dx.doi.org/10.3389/fpsyt.2018.00733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335386/
https://www.ncbi.nlm.nih.gov/pubmed/30687138
http://dx.doi.org/10.3389/fpsyt.2018.00733

Ejemplares similares